These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
228 related items for PubMed ID: 31371444
1. Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. Stagg HR, Bothamley GH, Davidson JA, Kunst H, Lalor MK, Lipman MC, Loutet MG, Lozewicz S, Mohiyuddin T, Abbara A, Alexander E, Booth H, Creer DD, Harris RJ, Kon OM, Loebinger MR, McHugh TD, Milburn HJ, Palchaudhuri P, Phillips PPJ, Schmok E, Taylor L, Abubakar I, London INH-R TB study group. Eur Respir J; 2019 Oct; 54(4):. PubMed ID: 31371444 [Abstract] [Full Text] [Related]
5. Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen. Lempens P, Decroo T, Aung KJM, Hossain MA, Rigouts L, Meehan CJ, Van Deun A, de Jong BC. Int J Infect Dis; 2020 Nov; 100():357-365. PubMed ID: 32829049 [Abstract] [Full Text] [Related]
6. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D. Lancet Respir Med; 2018 Apr; 6(4):265-275. PubMed ID: 29595509 [Abstract] [Full Text] [Related]
9. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Nolan CM, Goldberg SV. Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140 [Abstract] [Full Text] [Related]
14. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Ziganshina LE, Titarenko AF, Davies GR. Cochrane Database Syst Rev; 2013 Jun 06; 2013(6):CD004795. PubMed ID: 23744519 [Abstract] [Full Text] [Related]
15. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study. Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, Skrahina A, Dravniece G, Kuksa L, Rich M, Khachatryan N, Germanovych M, Kadyrov A, Terleieva I, Akhundova I, Adenov M, Durdyeva M, Kiria N, Parpieva N, Yatskevich N, Jumayev R, Nurov R, Diktanas S, Vilc V, Migliori GB, Yedilbayev A. Lancet Infect Dis; 2024 Oct 06; 24(10):1151-1161. PubMed ID: 38880112 [Abstract] [Full Text] [Related]